Sun, Jan 25, 2015, 6:52 PM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Xenoport, Inc. Message Board

  • wmjack50 wmjack50 Mar 22, 2013 9:21 AM Flag

    Horizant future sales--Why XNPT will succeed vs why GSK failed

    GSK's drug Requip for RLS has sales over $300 million annually now- thus GSK would be killing its own drug by pushing Horizant-GSK's generous legal settlement with Xnpt indicates this is the case also---Now the RLS or Willis Ekbom Disease Foundation discourages the use of dopaminergic drugs (Requip is one) for RLS due to studies that show increased heart failure and augmentation (RLS increases) Now Horizant is the only FDA approved drug for RLS that is not a dopaminergic drug and the only extended release gabapentin drug that is effective for RLS through the whole sleep cycle---

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
8.60-0.22(-2.49%)Jan 23 4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.